Hero

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

1

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

2

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

3

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

4

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Celyad Announces Board of Directors Evolution with New Appointment

Celyad Announces Board of Directors Evolution with New Appointment

Discover all news

Carousel

Social Feed

RT @LifeSci_PR: CEO of @CelyadSA, Filippo Petti (@filpetti), recently spoke with @pharmasalmanac on developing CAR-T therapies that use nat…

4 days ago

RT @LifeSci_PR: CEO of @CelyadSA, Filippo Petti (@filpetti), recently spoke with @pharmasalmanac on developing CAR-T therapies that use nat…

Interview de Michel Lussier, Président du CA de Celyad dans l'Echo de ce matin. https://t.co/hi30EdQq6J

5 days ago

Interview de Michel Lussier, Président du CA de Celyad dans l'Echo de ce matin. https://t.co/hi30EdQq6J

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting https://t.co/Xy1AOPmkX0 $CYAD #ASH2019

5 days ago

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting https://t.co/Xy1AOPmkX0 $CYAD #ASH2019

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell man… https://t.co/zXGD6DwaL6

6 days ago

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell man… https://t.co/zXGD6DwaL6

RT @LifeSci_PR: CEO of @CelyadSA, Filippo Petti (@filpetti), recently spoke with @pharmasalmanac on developing CAR-T therapies that use nat…

4 days ago

RT @LifeSci_PR: CEO of @CelyadSA, Filippo Petti (@filpetti), recently spoke with @pharmasalmanac on developing CAR-T therapies that use nat…

Interview de Michel Lussier, Président du CA de Celyad dans l'Echo de ce matin. https://t.co/hi30EdQq6J

5 days ago

Interview de Michel Lussier, Président du CA de Celyad dans l'Echo de ce matin. https://t.co/hi30EdQq6J

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting https://t.co/Xy1AOPmkX0 $CYAD #ASH2019

5 days ago

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting https://t.co/Xy1AOPmkX0 $CYAD #ASH2019

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell man… https://t.co/zXGD6DwaL6

6 days ago

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell man… https://t.co/zXGD6DwaL6